The Relative Strength of Royalty Pharma

RPRX is a new IPO that came out in June 16 forming a big couple of the entire company. The company has been around for years recently IPO to raise more money. They actually have a piece of Abveys blood cancer drug, vertes, cystic fibrosis, biogen multiple sclerosis, giliars HIV. So they're growing cash flows at about 22% adjusted and they should be compounding at seven to 10% per year to 2025 as their estimates that they gave and they pay a yield.